102 related articles for article (PubMed ID: 27112638)
1. Lipid profiling of lipoprotein X: Implications for dyslipidemia in cholestasis.
Heimerl S; Boettcher A; Kaul H; Liebisch G
Biochim Biophys Acta; 2016 Aug; 1861(8 Pt A):681-7. PubMed ID: 27112638
[TBL] [Abstract][Full Text] [Related]
2. Controversy over the atherogenicity of lipoprotein-X.
Miida T; Hirayama S
Curr Opin Endocrinol Diabetes Obes; 2019 Apr; 26(2):117-123. PubMed ID: 30694826
[TBL] [Abstract][Full Text] [Related]
3. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.
Walli AK; Seidel D
J Clin Invest; 1984 Sep; 74(3):867-79. PubMed ID: 6470142
[TBL] [Abstract][Full Text] [Related]
4. Biochemistry and clinical relevance of lipoprotein X.
Narayanan S
Ann Clin Lab Sci; 1984; 14(5):371-4. PubMed ID: 6476782
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages.
Suzuki L; Hirayama S; Fukui M; Sasaki M; Hiroi S; Ayaori M; Terai S; Tozuka M; Watada H; Miida T
J Clin Lipidol; 2017; 11(1):110-118. PubMed ID: 28391876
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-X fifty years after its original discovery.
Fellin R; Manzato E
Nutr Metab Cardiovasc Dis; 2019 Jan; 29(1):4-8. PubMed ID: 30503707
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.
Sörös P; Böttcher J; Maschek H; Selberg O; Müller MJ
Hepatology; 1998 Nov; 28(5):1199-205. PubMed ID: 9794902
[TBL] [Abstract][Full Text] [Related]
8. [Studies on the structure and metabolism of lipoprotein-X (LP-X), the abnormal plasmalipoprotein in cholestasis (author's transl)].
Seidel D
Klin Wochenschr; 1977 Jul; 55(13):611-23. PubMed ID: 197298
[TBL] [Abstract][Full Text] [Related]
9. Formation of lipoprotein-X. Its relationship to bile compounds.
Manzato E; Fellin R; Baggio G; Walch S; Neubeck W; Seidel D
J Clin Invest; 1976 May; 57(5):1248-60. PubMed ID: 816809
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of two different homogeneous assays for LDL-cholesterol in lipoprotein-X-positive serum.
Fei H; Maeda S; Kirii H; Fujigaki S; Maekawa N; Fujii H; Wada H; Saito K; Seishima M
Clin Chem; 2000 Sep; 46(9):1351-6. PubMed ID: 10973865
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells.
Edwards CM; Otal MP; Stacpoole PW
Metabolism; 1993 Jul; 42(7):807-13. PubMed ID: 8345791
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein abnormalities in cholestasis. I. Electrophoretic and ultracentrifugal analyses.
Watanabe M
Acta Med Okayama; 1979 Aug; 33(4):269-85. PubMed ID: 227230
[TBL] [Abstract][Full Text] [Related]
13. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry.
Wiesner P; Leidl K; Boettcher A; Schmitz G; Liebisch G
J Lipid Res; 2009 Mar; 50(3):574-585. PubMed ID: 18832345
[TBL] [Abstract][Full Text] [Related]
14. [Lipoprotein X (LP-X) in the differential diagnosis of cholestasis in children, with special reference to biliary atresia].
Duchnowska A; Wach K; Poradowska W
Probl Med Wieku Rozwoj; 1979; 8():84-91. PubMed ID: 263531
[TBL] [Abstract][Full Text] [Related]
15. Use of therapeutic plasma exchange to remove lipoprotein X in a patient with vanishing bile duct syndrome presenting with cholestasis, pseudohyponatremia, and hypercholesterolemia: A case report and review of literature.
Jung Y; Nelson HA; Lin DM
J Clin Apher; 2024 Feb; 39(1):e22105. PubMed ID: 38334173
[TBL] [Abstract][Full Text] [Related]
16. [Chylomicron metabolism in experimental cholestasis].
Damião AO; Sipahi AM; Quintão EC
Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(5):207-10. PubMed ID: 2636994
[TBL] [Abstract][Full Text] [Related]
17. Development and application of a high throughput one-pot extraction protocol for quantitative LC-MS/MS analysis of phospholipids in serum and lipoprotein fractions in normolipidemic and dyslipidemic subjects.
Gardner MS; Kuklenyik Z; Lehtikoski A; Carter KA; McWilliams LG; Kusovschi J; Bierbaum K; Jones JI; Rees J; Reis G; Pirkle JL; Barr JR
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1118-1119():137-147. PubMed ID: 31035135
[TBL] [Abstract][Full Text] [Related]
18. [The X of dyslipemias].
Merino Viveros M; Vega Piñero B; Gil Ares F; Guijarro de Armas MG; Montaño Martinez JM; Navea Aguilera C
Nutr Hosp; 2014 Apr; 29(4):953-5. PubMed ID: 24679041
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-X.
Narayanan S
CRC Crit Rev Clin Lab Sci; 1979 Aug; 11(1):31-51. PubMed ID: 389551
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro relationship between lipoprotein-X and bile salts in cholestasis.
Frisón JC; Ras MR; Rubiés-Prat J; Salvá JA; Masdeu S; Bacardí R
Digestion; 1979; 19(6):411-4. PubMed ID: 535670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
